Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Table 1 Main series of neoadjuvant therapy in locally advanced renal cell carcinoma

Ref.	No.	Therapy	Median size	% median reduction	Partial response	< 30% reduction	% cases tumour shrinkage	Toxicity Garde 3-4
Thomas et al[45]	19	Sunitinib	10.5	24%	3	8	42%	37%
Hellenthal et al[46]	20	Sunitinib	7	27.90%	2	15	85%	30%
Silberstein et al[47]	14	Sunitinib	7	21%	4	10	100%	3 urine leaks
Kondo et al[48]	9	Sunitinib/sorafenib	-	9%-30%	3	6	100%	2 major surgery complications
Rini et al[49]	28	Sunitinib	-	22%	-	-	-	-
Powles et al[50]	52	Sunitinib	-	-	-	-	73%	27%
Bex et al[51]	10	Sunitinib	-	14%			60%
Kats-Ugurlu et al[52]	10	Sorafenib	7.5	-	-	-	-	-
Cowey et al[53]	30	Sorafenib	8.7	9.60%	2	23	80%	-
Karam et al[54]	24	Axitinib	-	28.30%	11	-	100%	41.70%